Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius AP-32 + Lactobacillus rhamnosus bv-77 + Bifidobacterium animalis CP-9
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A multi-strain probiotic blend developed by Glac Biotech Co., Ltd., comprising *Lactobacillus salivarius* AP-32, *Lactobacillus rhamnosus* bv-77, and *Bifidobacterium animalis* CP-9, typically formulated in a 1:1:8 ratio. This live biotherapeutic product is administered orally and is primarily investigated for the treatment of childhood obesity and associated dyslipidemia. Its mechanism of action involves reshaping obesity-related gut dysbiosis to improve lipid metabolism and reduce systemic inflammation. Clinical trial results demonstrate that supplementation significantly reduces body mass index (BMI), serum total cholesterol, low-density lipoprotein (LDL), leptin, and tumor necrosis factor-alpha (TNF-α), while concurrently increasing high-density lipoprotein (HDL) and adiponectin levels. The product's efficacy is linked to the modulation of ether lipid metabolism and the enrichment of beneficial gut microbes.
- Other names
- multi-strain probiotic blendmulti-strain probiotic supplement
02
Targets
AdipoR (Adiponectin receptor)TNFA (Tumor necrosis factor alpha (soluble))LEP (Leptin)
Beyond the preview
Go deeper on Lactobacillus salivarius AP-32 + Lactobacillus rhamnosus bv-77 + Bifidobacterium animalis CP-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius AP-32 + Lactobacillus rhamnosus bv-77 + Bifidobacterium animalis CP-9.